MeVis Medical Solutions AG (XTER:M3V) Return-on-Tangible-Equity : 29.86% (As of Mar. 2024)

MeVis Medical Solutions AG Return-on-Tangible-Equity Chart

MeVis Medical Solutions AG Annual Data
	Trend	Dec13	Dec14	Dec15	Sep17	Sep18	Sep19	Sep20	Sep21	Sep22	Sep23
Return-on-Tangible-Equity		Get a 7-Day Free Trial					45.43	32.02	25.50	43.69	27.60

MeVis Medical Solutions AG Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Return-on-Tangible-Equity	Get a 7-Day Free Trial															38.38	49.01	20.52	34.68	29.86

Competitive Comparison of MeVis Medical Solutions AG's Return-on-Tangible-Equity

For the Health Information Services subindustry, MeVis Medical Solutions AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MeVis Medical Solutions AG's Return-on-Tangible-Equity Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, MeVis Medical Solutions AG's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where MeVis Medical Solutions AG's Return-on-Tangible-Equity falls into.

MeVis Medical Solutions AG Return-on-Tangible-Equity Calculation

MeVis Medical Solutions AG's annualized Return-on-Tangible-Equity for the fiscal year that ended in Sep. 2023 is calculated as

MeVis Medical Solutions AG's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

MeVis Medical Solutions AG  (XTER:M3V) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.

Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.

MeVis Medical Solutions AG Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of MeVis Medical Solutions AG's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

MeVis Medical Solutions AG (XTER:M3V) Business Description